BNTC Stock Analysis: Buy, Sell, or Hold?
BNTC - Benitec Biopharma Inc. Common Stock
$11.36
0.18 (1.61%)
▲
5d:
+8.19%
30d:
-4.14%
90d:
-5.41%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When BNTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BNTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BNTC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BNTC is currently trading at $11.36, which is considered fair relative to its 30-day fair value range of $10.70 to $11.77.
Technical Outlook: Technically, BNTC is showing sideways momentum. The price is approaching resistance at $11.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BNTC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $25.80 (+130.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BNTC is showing sideways momentum. The price is approaching resistance at $11.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BNTC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $25.80 (+130.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.70 -
$11.77
Company Quality Score
56/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.8% below Wall St target ($25.80)
Trading Range Analysis
30-Day Trading Range
$10.70 -
$11.77
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$3.66
(32.2%)
Support & Resistance Levels
Support Level
$10.00
Resistance Level
$11.66
Current Trend
Sideways
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.75
Wall Street Target
$25.80
(+130.8%)
Revenue Growth (YoY)
12.5%
Share & Embed Analysis
Last updated: June 15, 2026 1:31 PM ET
Data refreshes hourly during market hours. Next update: 2:31 PM
Data refreshes hourly during market hours. Next update: 2:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTC showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Suvretta Capital Managem…
BUY
77387 shares
2025-12-29
Suvretta Capital Managem…
BUY
16836 shares
2025-12-26
Suvretta Capital Managem…
BUY
50000 shares
2025-12-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
